Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lanthio Pharma BV

Division of MorphoSys AG

Latest From Mindray Medical International Ltd.

Sinovac Evaluating Competing Take-Private Offers

Beijing-based vaccines group Sinovac Biotech is evaluating two privatization proposals after competing offers from its CEO and an EV17 vaccine rival have emerged in recent days.

BioPharmaceutical China

Medtechs Told: Change Commercial Models Or Be Left Behind

Medical device companies working on the global stage are undergoing price and innovation productivity pressures just at the time that the markets are demanding a different type of service delivery from their suppliers. Smart manufacturers are reacting positively, with new commercial models, but they remain the exception to the rule, says the Boston Consulting Group, which is soon to release the second edition of its commercial benchmarking initiative.

Medical Device Strategy

Another China Player To Watch? Sinocare Moves Into US Via Nipro Deal

Sinocare Group, a Chinese specialist in biosensor-based blood glucose monitoring devices, is expanding into the US market after agreeing to buy Nipro’s diabetes business, Nipro Diagnostics.

Medical Device China

BeiGene Takes Different Path In Seeking $100m US IPO

Two well recognized Chinese biopharma companies, BeiGene and Hutchison China MediTech, have recently filed for initial public offerings of American Depositary Shares on the US Nasdaq market, with the aim of becoming integrated companies able to tap global markets. Both see good reasons for pursuing a path different to other Chinese peers that have recently delisted in the US.

BioPharmaceutical China
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • MorphoSys AG
  • Senior Management
  • Heinz Schwer, PhD, MBA, CEO
    Gert Moll, PhD, CSO
    Sjoerd Wadman, VP, R&D
    Michiel Lodder, PhD, VP, Bus. Dev.
  • Contact Info
  • Lanthio Pharma BV
    Phone: 50 30 50 240
    P.O. Box 719 Groningen, 9700 AS